NPM1 and acute myeloid leukemia: This section reviews the principal clinical settings in which venetoclax-based regimens are employed in NPM1-mutated AML, focusing on overall response rates, MRD clearance, remission duration, and the emerging possibility of planned therapy discontinuation.